Healthcare provider profile · identity verified

Zachary John Engelbert, D.O

Family Practice · LITTLETON, CO · NPI 1740508365

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	313	60
Levothyroxine Sodium	Levothyroxine Sodium	272	36
Amlodipine Besylate	Amlodipine Besylate	230	40
Furosemide	Furosemide	217	48
Lisinopril	Lisinopril	185	37
Gabapentin	Gabapentin	174	33
Eliquis	Apixaban	163	28
Omeprazole	Omeprazole	156	30
Metoprolol Succinate	Metoprolol Succinate	151	29
Rosuvastatin Calcium	Rosuvastatin Calcium	150	26
Potassium Chloride	Potassium Chloride	124	28
Losartan Potassium	Losartan Potassium	118	23
Mirtazapine	Mirtazapine	106	21
Sertraline Hcl	Sertraline Hcl	104	19
Pantoprazole Sodium	Pantoprazole Sodium	99	21
Famotidine	Famotidine	85	13
Quetiapine Fumarate	Quetiapine Fumarate	85	18
Carvedilol	Carvedilol	80	suppressed
Duloxetine Hcl	Duloxetine Hcl	73	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	69	15
Trazodone Hcl	Trazodone Hcl	67	suppressed
Metformin Hcl	Metformin Hcl	65	12
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	63	16
Trulicity	Dulaglutide	62	suppressed
Clopidogrel	Clopidogrel Bisulfate	59	12
Mirabegron Er	Mirabegron	58	12
Tamsulosin Hcl	Tamsulosin Hcl	57	12
Albuterol Sulfate Hfa	Albuterol Sulfate	53	28
Bupropion Xl	Bupropion Hcl	52	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	51	suppressed
Alendronate Sodium	Alendronate Sodium	50	13
Fluticasone Propionate	Fluticasone Propionate	45	22
Levetiracetam	Levetiracetam	42	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	42	suppressed
Oxycodone Hcl	Oxycodone Hcl	42	13
Memantine Hcl	Memantine Hcl	40	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	40	suppressed
Tramadol Hcl	Tramadol Hcl	39	17
Buspirone Hcl	Buspirone Hcl	36	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	35	suppressed
Myrbetriq	Mirabegron	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Ropinirole Hcl	Ropinirole Hcl	32	suppressed
Donepezil Hcl	Donepezil Hcl	31	suppressed
Risperidone	Risperidone	31	suppressed
Baclofen	Baclofen	30	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Atenolol	Atenolol	28	suppressed
Finasteride	Finasteride	28	suppressed
Allopurinol	Allopurinol	27	suppressed
Clonazepam	Clonazepam	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Olanzapine	Olanzapine	27	suppressed
Prednisone	Prednisone	27	16
Xarelto	Rivaroxaban	27	suppressed
Amiodarone Hcl	Amiodarone Hcl	26	suppressed
Azithromycin	Azithromycin	26	suppressed
Fluticasone-Salmeterol Hfa	Fluticasone Propion/Salmeterol	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Spironolactone	Spironolactone	25	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	25	suppressed
Ondansetron Odt	Ondansetron	24	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	23	suppressed
Aripiprazole	Aripiprazole	22	suppressed
Nebivolol Hcl	Nebivolol Hcl	22	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	21	suppressed
Fluticasone-Vilanterol	Fluticasone/Vilanterol	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Lamotrigine	Lamotrigine	21	suppressed
Linzess	Linaclotide	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Modafinil	Modafinil	19	suppressed
Nexlizet	Bempedoic Acid/Ezetimibe	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	14
Carbidopa-Levodopa	Carbidopa/Levodopa	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Prolia	Denosumab	17	12
Tiotropium Bromide	Tiotropium Bromide	17	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	16	suppressed
Rexulti	Brexpiprazole	16	suppressed
Cephalexin	Cephalexin	15	15
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Divalproex Sodium Er	Divalproex Sodium	15	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Glipizide	Glipizide	15	suppressed
Hydroxyurea	Hydroxyurea	15	suppressed
Jardiance	Empagliflozin	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Primidone	Primidone	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Varenicline Tartrate	Varenicline Tartrate	15	suppressed
Carbamazepine Er	Carbamazepine	14	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Ozempic	Semaglutide	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Topiramate	Topiramate	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Colchicine	Colchicine	12	suppressed
Insulin Aspart	Insulin Aspart	12	suppressed
Lacosamide	Lacosamide	12	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	12	suppressed
Vagifem	Estradiol	12	suppressed
Cilostazol	Cilostazol	11	suppressed
Clozapine	Clozapine	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	11	suppressed
Lorazepam Intensol	Lorazepam	11	suppressed
Lyrica	Pregabalin	11	suppressed
Nystop	Nystatin	11	suppressed
Pregabalin	Pregabalin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error